

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Multiple Technology Appraisal (MTA)**

**Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor**

**Expert statement declaration form**

Please sign and return by email to:  
Jeremy.Powell@nice.org.uk


If email is not possible, please return by fax to Jeremy Powell  
on 020 7061 9830

or by post to: NICE, MidCity Place, 71 High Holborn, London WC1V 6NA

I confirm that:

- I agree with the content of the submission from the **British Society for Rheumatology** and consequently I will not be submitting a personal statement.

Name: Dr Chris Deighton

Signed: 

Date: 18/12/09